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Abstract: The liver is the primary organ for the metabolic degradation of xenobiotics. Transmembrane
transport proteins from the ABC and the SLC families mediate the uptake of endogenous compounds and
xenobiotics into the hepatocyte as well as their elimination from the cells. Multiple processes are involved.
The uptake of xenobiotics in hepatocytes is mediated by organic anion transporting polypeptides (OATPs)
and by organic anion and cation transporters (OATs and OCTs). The elimination of drugs and metabolites
from the liver cell back to the bloodstream is accomplished mainly by multidrug resistance-associated
protein 3 (MRP3) and MRP4, while the elimination towards the biliary canaliculi is mediated by several
different transporters (MRP2, BCRP, MDR1 and MATE1). Since bile acids and their salts are toxic
detergents for hepatocytes, they have to be eliminated efficiently. This task is accomplished by the
bile salt export pump BSEP. Two further transporters, MDR3 and ATP8B1 are involved in the proper
constitution of bile. All these transporters can be influenced, mainly inhibited by a number of drugs,
but also by metabolites from endogenous compounds such as estrogens. Additionally, rare monogenetic
diseases exist which can be explained by absence of function or dysfunction of specific hepatic transporters,
such as progressive familial intrahepatic cholestasis type 2 by genetic modifications in BSEP that lead to
a loss of transporter function. Functional impairment of other transporters by genetics or by drugs also
leads to liver injury, a potentially life-threatening disease that is still not fully understood. Hence, the
interplay between drugs and hepatic transporters is multiple, and the knowledge of this interplay helps in
understanding the etiology and molecular mechanisms behind some forms of (drug-induced) liver injury.
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Abstract  8 
The liver is the primary organ for the metabolic degradation of xenobiotics. Transmembrane transport 9 
proteins from the ABC and the SLC families mediate the uptake of endogenous compounds and 10 
xenobiotics into the hepatocyte as well as their elimination from the cells. Multiple processes are 11 
involved. The uptake of xenobiotics in hepatocytes is mediated by organic anion transporting 12 
polypeptides (OATPs) and by organic anion and cation transporters (OATs and OCTs). The 13 
elimination of drugs and metabolites from the liver cell back to the bloodstream is accomplished mainly 14 
by multidrug resistance-associated protein 3 (MRP3) and MRP4, while the elimination towards the 15 
biliary canaliculi is mediated by several different transporters (MRP2, BCRP, MDR1 and MATE1). 16 
Since bile acids and their salts are toxic detergents for hepatocytes, they have to be eliminated 17 
efficiently. This task is accomplished by the bile salt export pump BSEP. Two further transporters, 18 
MDR3 and ATP8B1 are involved in the proper constitution of bile. All these transporters can be 19 
influenced, mainly inhibited by a number of drugs, but also by metabolites from endogenous 20 
compounds such as estrogens. Additionally, rare monogenetic diseases exist which can be explained 21 
by absence of function or dysfunction of specific hepatic transporters, such as progressive familial 22 
intrahepatic cholestasis type 2 by genetic modifications in BSEP that lead to a loss of transporter 23 
function. Functional impairment of other transporters by genetics or by drugs also leads to liver injury, 24 
a potentially life-threatening disease that is still not fully understood. Hence, the interplay between 25 
drugs and hepatic transporters is multiple, and the knowledge of this interplay helps in understanding 26 
the etiology and molecular mechanisms behind some forms of (drug-induced) liver injury.  27 
 28 
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 29 
Introduction  30 
Besides drug metabolizing enzymes, transmembrane drug transporters exert a relevant influence on 31 
the pharmacokinetics, and consequently the pharmacodynamics, of several drugs. These transporters 32 
are responsible for either the uptake of drugs into a cell, or for their extrusion from the cell. Mainly two 33 
families of transmembrane transporters, which are involved in drug transport, exist: ATP-binding 34 
cassette transporters (ABC) and solute carrier transporters (SLC). Transporters from other classes 35 
infrequently also play a role in transmembrane drug transport. While SLC-transporters are either 36 
uptake or bidirectional transporters, transporters from the ABC family mediate efflux of drugs and 37 
metabolites from the cells into the bloodstream or into the bile. Additionally, hepatic transporters may 38 
be inhibited by drugs or their metabolites, while they are not transporting these drugs themselves.  39 
 40 
Drug transporters in the liver  41 
Since the liver is the main organ responsible for drug metabolism, both the uptake and the efflux of 42 
drugs and respective metabolites are in most cases transporter-mediated. The concept of transporter-43 
mediated uptake of compounds into the hepatocytes was first developed when it was shown that the 44 
uptake of bile salts at the basolateral side was not a mere passive diffusion, but a carrier-mediated, 45 
sodium-dependent process which followed Michaelis-Menten kinetics [1]. Molecular cloning later 46 
identified the sodium-taurocholate cotransporting polypeptide NTCP, gene symbol SLC10A1, as the 47 
responsible transporter [2, 3], which not only transports bile salts across the basolateral membrane of 48 
hepatocytes, but also statins [4], and even hepatitis B and D viruses [5, 6].  49 
 50 
Basolateral or sinusoidal uptake transporters  51 
Organic anion transporting polypeptides (OATPs)  52 
A number of other transport proteins in the basolateral membrane have been detected, cloned, and 53 
functionally characterized since the discovery of transporter-mediated uptake. Namely different 54 
members of the family of organic anion transporting polypeptides (OATPs) are present in hepatocytes. 55 
Although the first OATP cloned from human liver, OATP1A2 [7], later turned out not to be present in 56 
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hepatocytes, but to be mainly expressed in the neurons of the hippocampus and the frontal cortex [8], 57 
other members of this family of transporters are strongly expressed in human hepatocytes. The three 58 
OATPs most abundantly expressed in the liver are OATP1B1 (gene symbol SLCO1B1), OATP1B3 59 
(gene symbol SLCO1B3), and OATP2B1 (gene symbol SLCO2B1) [9]. These transporters act 60 
bidirectionally, and can mediate the uptake of amphipathic and anionic substances in exchange with 61 
reduced glutathione or bicarbonate. They have overlapping substrate specificities, which are caused 62 
by the high degree of amino acid homology between the three transporters [10]. Numerous 63 
endogenous compounds are transported into the hepatocyte by OATPs, but also xenobiotics act as 64 
substrates [11]. One of the most important class of drugs which are taken up into the liver cells by 65 
OATPs are statins, HMG-CoA-reductase inhibitors [12]. Inhibition of the OATP-mediated uptake of 66 
statins into the liver cell leads to increased statin concentrations in the bloodstream and may translate 67 
into concentration-dependent adverse effects of statins, such as myopathy. This has been shown e.g. 68 
for ciclosporin [13], or gemfibrozil, although the extent of effect may vary according to the 69 
pharmacokinetic properties of the statin [14]. Besides statins, methotrexate, fexofenadine, some 70 
angiotensin-II-receptor antagonists and angiotensin converting enzyme inhibitors are described as 71 
substrates for OATPs [11, 13, 15]. For OATP1B1, it has been shown that the presence of genetic 72 
variants which decrease transporter function lead to an increase in drug exposure in the blood 73 
(reviewed in [13]). Particularly the c.521T>C SNP (rs4149056) has been shown to increase the AUC 74 
of virtually all statins and hence leads to an increased rate of concentration-dependent adverse effects 75 
like myopathy. In a genome wide association study on markers for simvastatin toxicity which included 76 
more than 300’000 markers in 85 patients with simvastatin-induced myopathy and 90 controls, this 77 
SNP in OATP1B1 was the only functionally active SNP which was strongly associated with statin-78 
induced myopathy [16]. Clinically relevant drug-drug interactions due to inhibition of OATPs may also 79 
be expected for several further drugs such as rifampicin [17], octreotide [18] and tyrosine kinase 80 
inhibitors, which have been shown in vitro to inhibit hepatic OATP activity. While most tyrosine kinase 81 
inhibitors are substrates for OATP1B1 and OATP1B3 [19], pazopanib and nilotinib inhibit OATP1B1 82 
with IC50 values of 3.89±1.21 and 2.78±1.13 μM, respectively [20]. It has to be mentioned, however, 83 
that tyrosine kinase inhibitors are not selective inhibitors of OATPs, but that also OCT1, OAT3 and 84 
other hepatic transporters are inhibited by these drugs, depending on the individual tyrosine kinase 85 
inhibitor [21].  86 
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There are also inherited diseases linked to OATPs. The human Rotor syndrome, an autosomal 87 
recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and practically 88 
absent hepatic uptake of anionic diagnostic agents, is caused by genetic variants in OATP1B1 and 89 
OATP1B3 [22]. Physiologically, bilirubin is conjugated in the hepatocytes mainly by UGT1A1 before a 90 
substantial fraction is excreted back into the bloodstream by the multidrug resistance protein 3 (MRP3, 91 
ABCC3), which is also responsible for the canalicular excretion of bilirubin glucuronides. Thereafter, 92 
OATP1B1 and OATP1B3 mediate the reabsorption of conjugated bilirubin into the hepatocytes (so-93 
called “hepatocyte hopping”) [22]. Given the role of human OATP1B1/1B3 as bilirubin (glucuronide) 94 
uptake transporters, drug-drug interactions at the basolateral entry site of hepatocytes may lead to a 95 
reduced clearance of such endogenous substrates.  96 
 97 
Organic anion transporters (OATs)  98 
In addition to the role of OATPs, some members of the organic anion transporters are present in the 99 
sinusoidal membrane of hepatocytes. Besides transporting various endogenous compounds such as 100 
estrone-3-sulfate, cGMP and others, OAT2 (SLC22A7) mediates the uptake of different xenobiotics 101 
[23], e.g. entecavir [24] and tolbutamide [25], a clinical marker substrate for CYP2C9 activity [26]. 102 
Another OAT, which is present more exclusively in the liver, is OAT7 (SLC22A9), while OAT2 is also 103 
present in the kidneys. For OAT7, one of the few exogenous substrates, which are known to date, is 104 
pravastatin [27].  105 
 106 
Organic cation transporters (OCTs)  107 
Like OATs, OCTs are widely distributed throughout tissues and are present mainly in the kidneys, the 108 
liver and the intestines [28]. In humans, OCT1 (gene symbol SLC22A1) is present mainly in the liver, 109 
where it mediates the uptake of positively charged hydrophilic compounds. Metformin is a broadly 110 
used antidiabetic which is transported by OCTs, and it has been reported that the OCT1-mediated 111 
uptake of metformin can be inhibited by rosiglitazone and repaglinide, two other orally administered 112 
antidiabetics [28].  113 
 114 
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Basolateral efflux transporters  115 
Multidrug resistance-associated proteins (MRP3, MRP4)  116 
These basolateral efflux transporters belong to the class of ABC-transporters. While the 117 
aforementioned proteins are located in the basolateral membrane of hepatocytes, MRP2 is located at 118 
the canalicular side (see below). Besides expression in the liver, MRPs are present in many other 119 
tissues with a barrier function such as the lung, the intestinal cells or the blood-brain-barrier [29]. 120 
MRP3 (gene symbol ABCC3) and MRP4 (gene symbol ABCC4) seem to be present in higher 121 
concentrations in the liver. A large range of both endogenous and xenobiotic organic anions is 122 
transported by the MRPs. Since they were first discovered in the research elucidating mechanisms of 123 
resistance of tumor cells against antineoplastic agents, it is not surprising that among the xenobiotics 124 
extruded from the cells by MRPs are vinca alkaloids, methotrexate, alkylating agents, and nucleoside 125 
and nucleotide analogs [30]. Glutathione (GSH) plays an important role in the transport mechanism of 126 
MRP2, which is not yet fully understood. While some xenobiotics are extruded from the cell as GSH-127 
conjugates, the MRP-mediated transport of others is dependent on, or stimulated by, the presence of 128 
GSH at the transporter site [30]. This stimulation of transport of unmodified drugs by GSH has been 129 
shown e.g. vinblastine via MRP2 [31] in vitro. In contrast to this, MRP3 does not transport GSH or 130 
glutathione-conjugated substances, but shows a preference for glucuronidated compounds [30]. 131 
Methotrexate is also transported by MRP3 [29]. In mice, it has been shown that both Mrp3 and Mrp4 132 
are important for the elimination of acetaminophen metabolites from the hepatocytes towards the 133 
bloodstream [32, 33], while Mrp2 and Bcrp eliminate acetaminophen conjugates towards the bile [33]. 134 
Additionally, in mice, the efflux of morphine glucuronides to the bloodstream was mediated by Mrp3, 135 
while Mrp2 was the responsible transport mechanism for biliary elimination of morphine 3-glucuronide, 136 
the predominant morphine metabolite [34]. Additionally, MRP3 and MRP4 can also transport bile salts 137 
and their glucuronides to the bloodstream, which constitutes a salvage mechanism in the case that the 138 
main elimination pathway for bile salts via BSEP is impaired [35]. These findings underline the role of 139 
MRPs in the elimination of potentially toxic compounds from the hepatocytes. The expression of MRP4 140 
in the liver seems to be low, as is the case for MRP1 [30]. MRP4 transports a broad range of 141 
xenobiotics and contributes to the elimination of bile acids, uric acid, steroid hormones and cyclic 142 
nucleotides from the liver cell to the sinusoidal blood [36]. Since its expression is upregulated in 143 
cholestasis and other diseases with impaired biliary elimination of organic anions, and since this 144 
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upregulation is even more pronounced than the upregulation of MRP3, MRP4 may be an important 145 
way of detoxification of bile salts in cholestasis [30].  146 
 147 
Canalicular efflux transporters  148 
Bile salt export pump (BSEP)  149 
The bile salt export pump BSEP (gene symbol ABCB11) is the primary transporter for the extrusion of 150 
bile salts into the bile canaliculi [35], which acts against a steep concentration gradient [37]. Bile salts 151 
have detergent properties [38] and may damage mitochondria [39], which leads to cytotoxicity and 152 
liver injury [40]. There appears to be no backup transporter for the canalicular export of bile salts, so 153 
that the inactivation of BSEP leads to intracellular accumulation of bile salts and hence liver damage. 154 
Evidence for this is available both from the bench and from the clinics. An inherited inactivation of 155 
BSEP leads to progressive familial intrahepatic cholestasis (PFIC) type 2 [41]. Mutations in ABCB11 156 
causing less severe reductions in BSEP function have been identified as being causative for benign 157 
recurrent intrahepatic cholestasis (BRIC) type 2 [42]. Drugs and / or drug metabolites do not appear to 158 
be transported by BSEP, but may act as BSEP-inhibitors. Since the transporter can also be 159 
competitively inhibited by ciclosporin, rifampicin, glibenclamide, bosentan and a number of other drugs 160 
[35], acquired forms of intrahepatic cholestasis also exist which clinically manifest with elevated 161 
transaminases or even as drug-induced liver injury (DILI). However, besides intrahepatic cholestasis 162 
caused by transporter inhibition, there are other reasons why DILI may develop, and only some of 163 
them are fully understood [43]. A clinically great challenge is the early and specific diagnosis of DILI. 164 
Therefore, current research activities focus on the identification and validation of DILI-specific 165 
biomarkers [44]. The antidiabetic drug troglitazone was withdrawn from the market because of an 166 
elevated incidence of hepatotoxicity. This hepatotoxic potential of troglitazone may be explained by 167 
the BSEP-inhibiting properties of the main metabolite troglitazone sulfate [45]. The troglitazone 168 
example shows nicely that metabolites which are produced intrahepatically may be the causative 169 
agents for inhibition of a transporter function and hence hepatotoxicity. In vitro investigations may 170 
hence fail to show hepatotoxic potential of a drug, if only the parent compound and not the metabolites 171 
are tested. These findings underline the importance of BSEP for the elimination of bile salts. Bile salts 172 
are ligands for the nuclear receptor farnesoid-x-receptor (FXR) and regulate thereby their synthesis, 173 
conjugation and transport [46]. FXR ligand-activators may hence be useful in disease states like 174 
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cholestatic liver diseases where a FXR-mediated activation of transporter function may be beneficial 175 
[47]. Since bile salts play such an important role in some forms of DILI, they could also be useful as 176 
biomarkers for DILI caused by BSEP-inhibition [48].  177 
 178 
Multidrug resistance-associated protein 2 (MRP2)  179 
The multidrug resistance-associated protein 2 (gene symbol ABCC2) is another transporter of the 180 
MRP family, which is, in contrast to MRP1, 3, and 4, directed towards the canalicular system. 181 
Substrates for this transporter are drug metabolites, including methotrexate [49], acetaminophen-182 
glucuronide [33], ezetimibe and etoposide [50]. MRP2 is also expressed in the kidneys. Particularly in 183 
cholestatic conditions, MRP2 is also capable to extrude bile salts from the hepatocytes and thereby 184 
helps in mitigating the toxic effect of high intracellular bile salt concentrations [35]. The function of 185 
MRP2 is relevant for the biliary elimination of bilirubin-glucuronide. This becomes clear e.g. in patients 186 
who have genetic polymorphisms in ABCC2 which lead, by different mechanisms, to a loss of MRP2 187 
function, and which present with Dubin-Johnson syndrome, a rare, autosomal-recessive, hereditary 188 
disease which presents with conjugated hyperbilirubinemia [51]. Estrogen metabolites are involved in 189 
the development of cholestasis in women taking oral contraceptives, but also in cholestasis of 190 
pregnancy [35]. Estradiol-17β-glucuronide, which is a strongly cholestatic estradiol metabolite in 191 
animal experiments [52], has to be excreted into the bile via MRP2 in order to inhibit BSEP from the 192 
luminal side and thereby blocking the elimination of bile salts [35].  193 
 194 
Breast cancer resistance protein (BCRP)  195 
The expression of BCRP (gene symbol ABCG2) is not limited to the liver, as is the case for many 196 
other transporters. BCRP shows a broad substrate specificity. As this transporter was first identified in 197 
the context of chemotherapy, the irinotecan metabolite SN-38, topotecan, and doxorubicin are 198 
examples for BCRP substrates [53]. Also newer drugs like the tyrosine-kinase inhibitor sunitinib are 199 
both substrates and inhibitors of BCRP, as it has been shown in humans [54], in rat experiments using 200 
pantoprazole as an inhibitor of BCRP [55] and in cells overexpressing BCRP [56]. However, it has to 201 
be acknowledged that the impact of hepatic BCRP on the overall pharmacokinetics of BCRP 202 
substrates cannot readily be estimated, because BCRP is also present in the intestines and the 203 
page 8  
 
kidneys, where the effect of BCRP on the pharmacokinetics of drugs is probably much larger than at 204 
the canalicular side of liver cells.  205 
 206 
P-glycoprotein (Multidrug resistance gene product 1;MDR1)  207 
P-glycoprotein (gene symbol ABCB1) is the most prominent xenobiotic transporter present in virtually 208 
all tissues with barrier function. The transporter, which is also called multidrug resistance protein 1 209 
(MDR1), was first discovered and extensively investigated in the context of resistance of tumor cells 210 
against antineoplastic agents. The transporter mediates the elimination of a broad variety of 211 
xenobiotics from cells, and it shows wide overlap in substrate specificity with other outward-directed 212 
drug transporters such as the MRP-transporters MRP3 (at the basolateral hepatocyte membrane) and 213 
MRP2 (at the canalicular side of hepatocytes) [57]. Additionally, most drugs transported by MDR1 are 214 
also substrates for the most important drug-metabolizing cytochrome P450 enzyme, CYP3A4. The 215 
expression of P-glycoprotein at the canalicular membrane of hepatocytes is sevenfold lower than the 216 
expression in enterocytes of the small intestines, and a considerable interindividual variation has also 217 
been noted [57]. Although more than 100 genetic variants in the ABCB1 gene are known, clinical 218 
consequences are at best controversial [58]. The most frequent genetic variants C3435T (rs1045642) 219 
or C1236T (rs1128503) do not lead to amino acid exchanges, while the variant G2677T/A (rs2032582) 220 
is responsible for an amino acid exchange which appears to cause relatively small changes in P-221 
glycoprotein function [58, 59]. Since MDR1 is expressed in many tissues and cells and appears to be 222 
functionally more relevant in the intestines and the blood-brain-barrier in comparison to the 223 
hepatocyte, inhibition of MDR1 function by drugs such as verapamil or ritonavir [57, 60] usually leads 224 
to pharmacokinetic changes of the victim drug, which cannot be attributed to a single expression site. 225 
In summary, it may be possible that MDR1 is not as important in the liver as other drug transporters, 226 
and as MDR1 is important in other tissues such as the enterocytes or the endothelial cells at the 227 
blood-brain-barrier.  228 
 229 
Multidrug resistance gene product 3 (MDR3)  230 
The MDR3 transporter (gene symbol ABCB4) is a phosphatidylcholine transporter expressed also at 231 
the canalicular membrane of hepatocytes. It translocates phospholipids to the outer leaflet of the 232 
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membrane lipid bilayer. Since phospholipids are essential in bile in order to solubilize cholesterol and 233 
bile salts in mixed micelles, genetic deficiencies of this transporter lead to a spectrum of cholestatic 234 
liver diseases ranging from transient neonatal cholestasis to biliary cirrhosis in adults, some forms of 235 
cholelithiasis, but also progressive familial intrahepatic cholestasis type 3, intrahepatic cholestasis of 236 
pregnancy, and drug-induced cholestasis [61, 62]. Although the severe loss-of-function variants are 237 
rare, up to 60% of a phenotypically healthy European population presents with genetic variants in the 238 
ABCB4 gene [63]. Unlike its close relative MDR1, MDR3 appears to be a phospholipid transporter with 239 
no drugs as substrates. However, azole antifungals such as itraconazole, posaconazole and 240 
ketoconazole can act as inhibitors of MDR3 and thereby cause cholestatic liver injury, as it has been 241 
shown using a functional assay to measure MDR3 activity [64]. When the phospholipid excretion into 242 
the bile is inhibited, the bile becomes more toxic because of a reduction in formation of mixed micelles, 243 
which mitigate the toxic effect of bile salts towards the biliary epithelium. A number of other 244 
compounds has been identified as being inhibitors of MDR3. Most of these compounds are known as 245 
causes of drug-induced liver injury and have either been withdrawn from the market or have warnings 246 
in the drug information leaflets [65]. Interestingly, azole antifungals like many of these potentially 247 
hepatotoxic drugs are also inhibitors of BSEP, thereby leading to a dual mechanism by which they can 248 
cause drug-induced liver injury in susceptible patients.  249 
 250 
Type 4 P-type ATPase ATP8B1  251 
A third transport mechanism is necessary for appropriate bile formation and avoiding bile salt toxicity: 252 
ATP8B1. This canalicular transporter is a phosphatidylserine translocase or flippase. 253 
Phosphatidylserines serve to make the outer layer of the membrane more resistant against the 254 
detergent properties of bile acids [66]. Rare genetic variants in the ATP8B1 gene lead to a loss of 255 
function of this transporter, which manifests clinically as progressive familial intrahepatic cholestasis 256 
type 1 (PFIC1), also called Byler’s disease, or in less severe cases to benign recurrent intrahepatic 257 
cholestasis type 1 (BRIC1) [67, 68].  258 
 259 
Multidrug and toxin extrusion protein 1 (MATE1)  260 
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MATE transporters are abundantly expressed in the kidneys and play an important role in the tubular 261 
elimination of mainly cationic drugs and endogenous compounds [69]. In the canalicular membrane of 262 
hepatocytes, MATE1 (gene symbol SLC47A1) is expressed, but other MATE proteins have not been 263 
found [70]. It has been postulated that MATE1 presents a scavenger transport mechanism to P-264 
glycoprotein, because it shares various neutral and cationic organic substrates with this transporter 265 
like fexofenadine, levofloxacin and quinidine, and that substrates which are taken up into the liver cell 266 
by OCTs are (at least partially) extruded into the bile by MATE1 [69, 71]. Example substrates for this 267 
latter mechanism are metformin and cimetidine. However, MATE1 plays a more important role in the 268 
kidneys than in the liver, and data on the specific role of MATE1 in the liver is scarce.  269 
 270 
Further hepatic transmembrane transporters  271 
Besides these transmembrane transport proteins which have been relatively well characterized in the 272 
liver, other transporters such as the equilibrative nucleoside transporters ENT1 and ENT2 or the 273 
organic solute and steroid transporter, OST alpha-OST beta, exist in hepatocytes, but also in intestinal 274 
epithelial cells. The latter transporter is an unusual heterodimer, which is important in bile acid and 275 
steroid homeostasis. This transport mechanism is mainly expressed in enterocytes, but also on the 276 
basolateral membrane of hepatocytes [72]. In hypoxic states, the transport activity of OST alpha-OST 277 
beta is induced [73], and it has been shown that this transporter heterodimer can be transactivated by 278 
FXR [74], the nuclear receptor that mediates bile acid homeostasis.  279 
 280 
Conclusion  281 
The uptake of endogenous and foreign compounds into the liver cell is closely regulated by a number 282 
of specific transporters, as is the elimination of such compounds and their metabolites, which are 283 
formed intrahepatically towards the bile and back to the bloodstream. A particular function of 284 
hepatocytes is the formation of bile, which is both necessary and toxic because of its contents in bile 285 
salts. If BSEP, the transporter necessary for proper elimination of bile salts from hepatocytes, is 286 
impaired by genetic factors or inhibited by drugs and metabolites, liver injury by intrahepatic 287 
cholestasis develops. Functional impairment of other transporters by genetics or by drugs also leads 288 
to liver injury, a potentially life-threatening disease, which is still not fully understood. Hence, the 289 
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interplay between drugs and hepatic transporters is multiple, and the knowledge of this interplay helps 290 
in understanding the etiology and molecular mechanisms behind some forms of (drug-induced) liver 291 
injury.  292 
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